KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Financing Activities (2016 - 2026)

Neogenomics filings provide 17 years of Cash from Financing Activities readings, the most recent being -$338000.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 135.62% to -$338000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$201.6 million, a 4317.93% decrease, with the full-year FY2025 number at -$200.3 million, down 4410.98% from a year prior.
  • Cash from Financing Activities hit -$338000.0 in Q1 2026 for Neogenomics, down from $431000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $6.1 million in Q1 2022 to a low of -$202.4 million in Q2 2025.
  • Median Cash from Financing Activities over the past 5 years was $1.0 million (2022), compared with a mean of -$10.6 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 2971.88% in 2024 and later crashed 10396.69% in 2025.
  • Neogenomics' Cash from Financing Activities stood at $1.8 million in 2022, then dropped by 29.52% to $1.3 million in 2023, then tumbled by 45.91% to $687000.0 in 2024, then plummeted by 37.26% to $431000.0 in 2025, then crashed by 178.42% to -$338000.0 in 2026.
  • The last three reported values for Cash from Financing Activities were -$338000.0 (Q1 2026), $431000.0 (Q4 2025), and $765000.0 (Q3 2025) per Business Quant data.